Enhance the Value of Archival Tissue Samples with Paige OmniScreen™
Archival biospecimens hold significant potential for advancing cancer research, yet many are underutilized due to limited specimen information.
Paige OmniScreen* leverages novel AI technology to simultaneously screen over 1,200 clinically relevant biomarkers across multiple cancer types. This provides in-depth information about the tissue using standard H&E-stained slides, providing a tissue sparing alternative to traditional sequencing methods.
A Scalable, Cost-Effective Approach to Tissue Characterization
Comprehensive Biomarker Profiling
Predicts 1,228 biomarkers across 15 common cancers, including BRAF, EGFR, KRAS, MET, and FGFR3
Provides a tissue-sparing alternative to traditional molecular testing
Enhanced Tissue Characterization
Strengthens phenotype-genotype linkages, offering deeper insights into molecular tumor profiles
Enriches dataset quality for pharmaceutical companies and research organizations seeking well-characterized specimens
Operational & Cost Efficiencies
Delivers biomarker predictions in minutes, reducing reliance on manual pathology review and costly sequencing tests
Enables large-scale tissue characterization, making even extensive biospecimen collections more accessible and valuable
Optimized Specimen Utilization
Helps to differentiate tissue and enhance inventory information with deep molecular insights
Identifies high-value tissue samples for targeted oncology research, improving specimen demand and revenue potential
Increase the value of your pathology data with Paige OmniScreen™
Tissue characterization is faster, more efficient, and cost-effective.
Schedule a meeting today to explore how this technology can enhance the value of tissue collections and streamline molecular biomarker identification.
Not sure we can say more precise. Perhaps loss costly?
Schedule a meeting today
And discover how AI-driven pre-screening can optimize your research and clinical workflows